Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of 215.54 billion. The enterprise value is 233.81 billion.
| Market Cap | 215.54B |
| Enterprise Value | 233.81B |
Important Dates
The last earnings date was Friday, January 31, 2025.
| Earnings Date | Jan 31, 2025 |
| Ex-Dividend Date | Mar 11, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -2.72% |
| Shares Change (QoQ) | -1.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.88B |
Valuation Ratios
The trailing PE ratio is 18.05.
| PE Ratio | 18.05 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.11, with an EV/FCF ratio of 14.39.
| EV / Earnings | 19.58 |
| EV / Sales | 4.49 |
| EV / EBITDA | 11.11 |
| EV / EBIT | 14.25 |
| EV / FCF | 14.39 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.04 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 1.50 |
| Debt / FCF | 1.93 |
| Interest Coverage | 16.22 |
Financial Efficiency
Return on equity (ROE) is 26.28% and return on invested capital (ROIC) is 13.72%.
| Return on Equity (ROE) | 26.28% |
| Return on Assets (ROA) | 10.09% |
| Return on Invested Capital (ROIC) | 13.72% |
| Return on Capital Employed (ROCE) | 22.19% |
| Revenue Per Employee | 681,602 |
| Profits Per Employee | 157,361 |
| Employee Count | 75,883 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.20 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.99% in the last 52 weeks. The beta is 0.53, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +3.99% |
| 50-Day Moving Average | 100.57 |
| 200-Day Moving Average | 105.62 |
| Relative Strength Index (RSI) | 56.07 |
| Average Volume (20 Days) | 196,506 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novartis AG had revenue of 51.72 billion and earned 11.94 billion in profits. Earnings per share was 5.87.
| Revenue | 51.72B |
| Gross Profit | 38.91B |
| Operating Income | 16.32B |
| Pretax Income | 13.64B |
| Net Income | 11.94B |
| EBITDA | 20.66B |
| EBIT | 16.32B |
| Earnings Per Share (EPS) | 5.87 |
Balance Sheet
The company has 13.35 billion in cash and 31.40 billion in debt, giving a net cash position of -18.05 billion.
| Cash & Cash Equivalents | 13.35B |
| Total Debt | 31.40B |
| Net Cash | -18.05B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 44.13B |
| Book Value Per Share | 22.30 |
| Working Capital | 1.01B |
Cash Flow
In the last 12 months, operating cash flow was 17.62 billion and capital expenditures -1.37 billion, giving a free cash flow of 16.25 billion.
| Operating Cash Flow | 17.62B |
| Capital Expenditures | -1.37B |
| Free Cash Flow | 16.25B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.22%, with operating and profit margins of 31.55% and 23.09%.
| Gross Margin | 75.22% |
| Operating Margin | 31.55% |
| Pretax Margin | 26.37% |
| Profit Margin | 23.09% |
| EBITDA Margin | 39.95% |
| EBIT Margin | 31.55% |
| FCF Margin | 31.42% |
Dividends & Yields
Novartis AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 63.85% |
| Buyback Yield | 2.72% |
| Shareholder Yield | 2.72% |
| Earnings Yield | 5.54% |
| FCF Yield | 7.54% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novartis AG has an Altman Z-Score of 3.92.
| Altman Z-Score | 3.92 |
| Piotroski F-Score | n/a |